Roche signs up to $15 billion ADC partnership with China's Hansoh, paying $400 million upfront
Roche announced a new partnership with Chinese drugmaker Hansoh Pharmaceutical Group focused on antibody‑drug conjugates. The agreement includes an upfront payment of $400 million and the potential for total payments up to $15 billion.
Under the deal, Hansoh will contribute two preclinical ADC candidates and will develop additional candidates based on targets proposed by Roche. The specific drugs or disease areas were not disclosed.
The alliance marks Roche’s sixth licensing deal with a China‑based partner since August, putting the company ahead of its peers in the region according to BioPharma Dive data.
In separate news, Veradermics reported a positive outcome from a second late‑stage trial of its oral extended‑release minoxidil formulation for male pattern baldness.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that